NuCana (NCNA) elevates Ian Webster to CFO as oncology pipeline advances

Rhea-AI Filing Summary

NuCana plc, a clinical-stage biopharmaceutical company focused on improving cancer treatments, has appointed Ian Webster as Chief Financial Officer, effective June 1, 2026. He has been Interim CFO since June 2025 and previously served as Director of Finance after joining in 2019, and will continue as Principal Financial and Accounting Officer.

The company highlights its oncology pipeline, including NUC-7738 and NUC-3373. It plans to generate data in 2026 from the Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda in PD-1 inhibitor-resistant metastatic melanoma and to refine a potential registrational strategy in melanoma. NuCana also notes multiple anticipated data readouts and a cash runway anticipated to extend into 2029, supporting its clinical and strategic plans.

Key Figures

Effective CFO appointment date: June 1, 2026 Interim CFO tenure start: June 2025 Years of finance experience: More than 20 years +2 more

5 metrics

Effective CFO appointment date June 1, 2026 Ian Webster named Chief Financial Officer

Interim CFO tenure start June 2025 Ian Webster previously served as Interim CFO

Years of finance experience More than 20 years Ian Webster’s professional background

Cash runway Into 2029 Current cash and cash equivalents funding planned operations

Key upcoming data year 2026 Planned data from Phase 2 NuTide:701 study of NUC-7738

Key Terms

ProTide technology, PD-1 inhibitor-resistant metastatic melanoma, Phase 2, thymidylate synthase inhibitor, +1 more

5 terms

ProTide technology technical

"applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents"

PD-1 inhibitor-resistant metastatic melanoma medical

"evaluating NUC-7738 in combination with Keytruda ... in patients with PD-1 inhibitor-resistant metastatic melanoma"

A form of skin cancer that has spread to other parts of the body and no longer responds to PD‑1 inhibitor drugs, a common class of immunotherapies that boost the immune system to attack tumors. For investors, this describes a patient group with unmet medical need and a clear market opportunity for new treatments or combinations; think of it as a population for which the usual tool has dulled and companies are racing to invent a sharper one.

Phase 2 medical

"plans to generate data in 2026 from the Phase 2 NuTide:701 study"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

thymidylate synthase inhibitor medical

"NUC-3373 is a targeted thymidylate synthase (“TS”) inhibitor designed to overcome key pharmacological limitations"

forward-looking statements regulatory

"This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

(Commission File No. 001-38215)

NUCANA PLC

(Translation of registrant’s name into English)

3 Lochside Way

Edinburgh EH12 9DT

United Kingdom

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)  (7): ☐

Changes to Management

On June 1, 2026, NuCana plc (the “Company”) issued a press release announcing the appointment of Ian Webster to serve as the Company’s Chief Financial Officer. Mr. Webster has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining the Company in 2019. Mr. Webster will continue to serve as the Company’s Principal Financial Officer and Principal Accounting Officer. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Exhibits
99.1		Press Release, dated June 1, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NuCana plc
By:		/s/ Ian Webster
Name:		Ian Webster
Title:		Chief Financial Officer (Principal Financial and Accounting Officer)

Date: June 1, 2026

Exhibit 99.1

NuCana Appoints Ian Webster as Chief Financial Officer

Edinburgh, United Kingdom, June 1, 2026 (GLOBE NEWSWIRE)—NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining NuCana in 2019.

“We are delighted to appoint Ian as Chief Financial Officer,” said Hugh S. Griffith, Founder and Chief Executive Officer of NuCana. “Since joining NuCana, Ian has demonstrated deep financial expertise and a thorough understanding of our business. He will continue to shape our financial strategy as we advance our pipeline, including our plans to generate data in 2026 from the Phase 2 NuTide:701 study evaluating NUC-7738 in combination with Keytruda^® (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma and to prepare the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma.”

“I am honored to be appointed Chief Financial Officer at such an exciting time for NuCana,” said Ian Webster. “With multiple anticipated data readouts and a cash runway anticipated to extend into 2029, I look forward to helping advance the Company’s strategic priorities and long-term value creation.”

Ian brings more than 20 years of finance experience to the Chief Financial Officer role, including over a decade in senior leadership positions within the biopharmaceutical sector. His expertise spans financial management, public company reporting, audit, tax, mergers and acquisitions, as well as financial planning and analysis.

Prior to joining NuCana, Ian served as Group Financial Controller at Kyowa Kirin International plc, a specialty pharmaceutical company, from 2013 to 2019. Earlier in his career, he spent 11 years at PricewaterhouseCoopers LLP, where he was a senior manager in the audit and transaction services practices in the United Kingdom and Canada.

Ian is a chartered accountant with the Institute of Chartered Accountants of Scotland and holds a BSc Honours in Accounting and Finance from the University of Warwick.

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a targeted thymidylate synthase (“TS”) inhibitor designed to overcome key pharmacological limitations associated with other TS inhibitors. NUC-3373 has recently been evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer, and NuCana is currently evaluating further characterization of mode of action and target indications for further clinical studies of NUC-3373.

Forward-Looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; the Company’s financial strategy; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks,

uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

NuCana plc

Hugh S. Griffith

Chief Executive Officer

+44 131-357-1111

info@nucana.com

ICR Healthcare

Chris Brinzey

+1 339-970-2843

Chris.Brinzey@ICRHealthcare.com

FAQ

What executive change did NuCana (NCNA) report in this 6-K?

NuCana appointed Ian Webster as Chief Financial Officer, effective June 1, 2026. He previously served as Interim CFO since June 2025 and Director of Finance since 2019, and remains Principal Financial and Accounting Officer.

What experience does NuCana’s new CFO Ian Webster bring to the role?

Ian Webster brings more than 20 years of finance experience, including over a decade in senior biopharmaceutical roles. His background covers financial management, public reporting, audit, tax, M&A, and financial planning and analysis, plus earlier work at Kyowa Kirin International and PwC.

What are NuCana’s near-term clinical plans mentioned in the filing?

NuCana plans to generate data in 2026 from the Phase 2 NuTide:701 study evaluating NUC-7738 with Keytruda in PD-1 inhibitor-resistant metastatic melanoma. The company is also preparing the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma.

How long does NuCana expect its cash runway to last?

NuCana states that its current cash and cash equivalents are anticipated to fund planned operations into 2029. This projected runway is part of its forward-looking statements and underpins ongoing and planned clinical development activities.

Which cancer drug candidates are highlighted in NuCana’s pipeline?

NuCana highlights NUC-7738 and NUC-3373 as key product candidates. NUC-7738 is in a Phase 1/2 study including a Phase 2 melanoma cohort, while NUC-3373 has been evaluated in a Phase 1b/2 modular study in combination with pembrolizumab and docetaxel.

What is NuCana’s technology focus according to this report?

NuCana focuses on its proprietary ProTide technology, which aims to transform existing nucleoside analog chemotherapy agents into more effective and potentially better tolerated medicines. The goal is to generate higher active metabolite levels in cancer cells and improve treatment outcomes.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 10.7 KB